A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HS-10383 in Chinese adult subjects with refractory or unexplained chronic cough (RUCC).
A Randomized, Double-Blind, Placebo Controlled, Phase Ib Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple-Dose Escalation HS-10383 in Healthy Adult Subjects
This study will investigate the safety, tolerability and pharmacokinetics of ascending multiple doses of HS-10383 in healthy subjects using a randomized, double blind, placebo controlled, single center study design.
在中国健康成人受试者中评估HS-10383的安全性、耐受性及药代动力学特征的随机、双盲、安慰剂对照的I期临床试验
主要研究目的:评价HS-10383 在中国健康成年受试者中单次给药的安全性和耐受性。
次要研究目的:评价HS-10383 在中国健康成年受试者中单次给药的药代动力学特征。
100 项与 HS-10383 相关的专利(医药)